CoChat
Sign Up
Cited by 113Graphene and Nanomaterials ApplicationsNanoparticle-Based Drug DeliveryNanoplatforms for cancer theranostics

The DOI matches its Crossref record; 196 of the 198 references it cites were found in a registry or an index.

Toxicity of Carbon Nanotubes as Anti-Tumor Drug Carriers

Open access
Yan, Hongli, Xue, Zhifeng, Xie, Jiarong, Dong, Yixiao, Ma, Zhe, Sun, Xinru, Kebebe Borga, Dereje, Liu, Zhidong, Li, Jiawei·2019·International Journal of Nanomedicine
DOI 10.2147/ijn.s220087PMC PMC6946632
Open this paper in CoChat — free accountOpen PDF

Abstract

Nanoparticle drug formulations have enormous application prospects owing to achievement of targeted and sustained release drug delivery, improvement in drug solubility and reduction of adverse drug reactions. Recently, a variety of efficient drug nanometer carriers have been developed, among which carbon nanotubes (CNT) have been increasingly utilized in the field of cancer therapy. However, these nanotubes exert various toxic effects on the body due to their unique physical and chemical properties. CNT-induced toxicity is related to surface modification, degree of aggregation in vivo, and nanoparticle concentration. This review has focused on the potential toxic effects of CNTs utilized as anti-tumor drug carriers. The main modes by which CNTs enter target sites, the toxicity expressive types and the factors affecting toxicity are discussed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/ijn.s220087

Cites

196 of 196 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic diagram illustrating the cells entering process of anti-tumor nanometer preparation with CNTs as a carrier.
Figure 1 Schematic diagram illustrating the cells entering process of anti-tumor nanometer preparation with CNTs as a carrier.CC BY-NC · PubMed Central
Figure 2 This figure shows the sites that CNTs may accumulate after separation from anticancer drugs, resulting in toxicity to different organs. CNTs mainly cause damage and toxicity to organs such as heart, liver, lung, kidney, brain and embryo.
Figure 2 This figure shows the sites that CNTs may accumulate after separation from anticancer drugs, resulting in toxicity to different organs. CNTs mainly cause damage and toxicity to organs such as heart, liver, lung, kidney, brain and embryo.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

3 retracted

Show all 198 references

Research works printed but not linked: 3

  1. [63]Kang B, Dai Y, Chang S, et al. Cell response to carbon nanotubes: size-dependent intracellular uptake mechanism and subcellular fate. Small. 2010; 6: 2362– 2366. doi: 10.1002/smll.201001260 20878638 · DOI
  2. [89]Ying L, Yuliang Z, Baoyun S, et al. Understanding the toxicity of carbon nanotubes. Acc Chem Res. 2013; 46: 702– 713. doi: 10.1021/ar300028m 22999420 · DOI
  3. [105]TSUJI T, USUKURA J. Assessment on a biological toxicity caused by single-walled carbon nanotubes. Nano Biomed. 2012; 4: 125– 132.

Cited by

Sorted by citations

Related

See all

Metadata

Authors
Yan, H., Xue, Z., Xie, J., Dong, Y., Ma, Z., Sun, X., Kebebe Borga, D., Liu, Z., & Li, J.
Affiliations
Tianjin University of Traditional Chinese Medicine (CN)
Corresponding author
Liu, Zhidong
ORCID
Venue
International Journal of Nanomedicine
Publisher
Informa UK Limited
Published
2019-12
Volume
Volume 14
Pages
10179-10194
ISSN
  • 1176-9114 (ISSN-L)
  • 1178-2013
DOI
10.2147/ijn.s220087
PMC
PMC6946632
OpenAlex
W2997737850
Cited by
113
References
198
Citations by year
2026: 11 · 2025: 18 · 2024: 25 · 2023: 17 · 2022: 18 · 2021: 19 · 2020: 4
FWCI
0.82
Type
journal article
Language
en
Open access
Licence
Locations
  • International Journal of Nanomedicine (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Graphene and Nanomaterials Applications
  • Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
Keywords
carbon nanotubes, nanoparticle toxicity, nanoparticle drug delivery, cancer therapy, surface modification, nanoparticle aggregation, toxicity factors, targeted drug delivery
MeSH terms
Animals, Antineoplastic Agents, Drug Carriers, Humans, Solubility, Nanotubes, Carbon

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review